Product Name
CHST3, siRNA
Popular Item
Full Product Name
CHST3 siRNA (Human)
Product Synonym Names
Carbohydrate sulfotransferase 3; Chondroitin 6-O-sulfotransferase 1; C6ST-1; Chondroitin 6-sulfotransferase; Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 0; GST-0
Product Gene Name
CHST3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q7LGC8
Specificity
CHST3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CHST3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CHST3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CHST3 sirna
siRNA to inhibit CHST3 expression using RNA interference
Applications Tested/Suitable for CHST3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CHST3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_004264.2
[Other Products]
NCBI GenBank Nucleotide #
NM_004273.4
[Other Products]
UniProt Primary Accession #
Q7LGC8
[Other Products]
UniProt Secondary Accession #
O75099; Q52M30[Other Products]
UniProt Related Accession #
Q7LGC8[Other Products]
Molecular Weight
54,706 Da
NCBI Official Full Name
carbohydrate sulfotransferase 3
NCBI Official Synonym Full Names
carbohydrate (chondroitin 6) sulfotransferase 3
NCBI Official Symbol
CHST3??[Similar Products]
NCBI Official Synonym Symbols
HSD; C6ST; C6ST1
??[Similar Products]
NCBI Protein Information
carbohydrate sulfotransferase 3
UniProt Protein Name
Carbohydrate sulfotransferase 3
UniProt Synonym Protein Names
Chondroitin 6-O-sulfotransferase 1; C6ST-1; Chondroitin 6-sulfotransferase; Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 0; GST-0
Protein Family
Carbohydrate sulfotransferase
UniProt Gene Name
CHST3??[Similar Products]
UniProt Synonym Gene Names
C6ST-1; GST-0??[Similar Products]
UniProt Entry Name
CHST3_HUMAN
NCBI Summary for CHST3
This gene encodes an enzyme which catalyzes the sulfation of chondroitin, a proteoglycan found in the extracellular matrix and most cells which is involved in cell migration and differentiation. Mutations in this gene are associated with spondylepiphyseal dysplasia and humerospinal dysostosis. [provided by RefSeq, Mar 2009]
UniProt Comments for CHST3
CHST3: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of the N-acetylgalactosamine (GalNAc) residue of chondroitin. Chondroitin sulfate constitutes the predominant proteoglycan present in cartilage and is distributed on the surfaces of many cells and extracellular matrices. Can also sulfate Gal residues of keratan sulfate, another glycosaminoglycan, and the Gal residues in sialyl N- acetyllactosamine (sialyl LacNAc) oligosaccharides. May play a role in the maintenance of naive T-lymphocytes in the spleen. Defects in CHST3 are a cause of spondyloepiphyseal dysplasia with congenital joint dislocations (SEDC-JD). A bone dysplasia clinically characterized by dislocation of the knees and/or hips at birth, clubfoot, elbow joint dysplasia with subluxation and limited extension, short stature, and progressive kyphosis developing in late childhood. The disorder is usually evident at birth, with short stature and multiple joint dislocations or subluxations that dominate the neonatal clinical and radiographic picture. During childhood, the dislocations improve, both spontaneously and with surgical treatment, and features of spondyloepiphyseal dysplasia become apparent, leading to arthritis of the hips and spine with intervertebral disk degeneration, rigid kyphoscoliosis, and trunk shortening by late childhood. Belongs to the sulfotransferase 1 family. Gal/GlcNAc/GalNAc subfamily.
Protein type: Glycan Metabolism - chondroitin sulfate biosynthesis; Membrane protein, integral; EC 2.8.2.17; Transferase
Chromosomal Location of Human Ortholog: 10q22.1
Cellular Component: Golgi membrane; integral to membrane
Molecular Function: chondroitin 6-sulfotransferase activity; sulfotransferase activity; proteoglycan sulfotransferase activity
Biological Process: chondroitin sulfate metabolic process; sulfur metabolic process; chondroitin sulfate biosynthetic process; glycosaminoglycan metabolic process; carbohydrate metabolic process; T cell homeostasis; pathogenesis
Disease: Spondyloepiphyseal Dysplasia With Congenital Joint Dislocations; Multiple Joint Dislocations, Short Stature, Craniofacial Dysmorphism, And Congenital Heart Defects
Research Articles on CHST3
1. Sequencing of CHST3 detected a previously unreported homozygous duplication c.407_426dup (p.Thr143Cysfs*80). The mutation is predicted to lead to frameshift and introduction of a premature stopcodon.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
